Hepatocellular Carcinoma Trial Landscape (June 2026)

Last updated: Jun 27, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT06050252	2	Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	PD-L1 -- immune checkpoint inhibitor + chemotherapy
NCT07291076	1, 2	A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)	Unknown mechanism
NCT07110233	—	Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma	Yttrium-90 -- radioembolization (TheraSphere®)
NCT07166406	3	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	PD-L1 + VEGF -- immune checkpoint blockade plus anti-angiogenic antibody (immune checkpoint inhibitors + anti-VEGF antibody)
NCT06824974	—	Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer	Unknown mechanism

Top Sponsors

Sponsor	Recruiting trials
Sun Yat-sen University	39
Second Affiliated Hospital of Guangzhou Medical University	17
Fudan University	16
Tianjin Medical University Cancer Institute and Hospital	15
Tongji Hospital	13

Geographic Distribution

Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Aug 2026	NCT07430202	A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)	DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors
Jul 1, 2026	NCT07365839	Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma	PD-1 -- immune checkpoint inhibitor (cemiplimab) +/- CTLA-4 inhibitor (fianlimab)
Jun 30, 2026	NCT07627191	GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer	GLP-1 receptor -- receptor agonist (GLP-1 RA)
Jun 2026	NCT07587034	HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer	VEGFR2 -- tyrosine kinase inhibitor (apatinib); PD-1 -- immune checkpoint inhibitor (camrelizumab)
May 29, 2026	NCT07583316	A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors	MAGE-A1 + HLA-A*02:01 -- bispecific T-cell engager
May 19, 2026	NCT07547553	A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC	FGF19 -- monoclonal antibody
May 1, 2026	NCT07446257	THIO and Cadonilimab in Resectable Hepatocellular Carcinoma	PD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog
Apr 30, 2026	NCT07522411	Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma	Chemotherapy (FOLFOX) + PD-1 inhibitor + VEGF inhibitor + TACE -- combination therapy

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.